Research on targeted therapy for BRAF has focused on the V600E mutation, but class II and III BRAF mutations have also been found to be the driving mutations in lung adenocarcinoma, and the rate of non-BRAF V600E mutations can be as high as 50–80% in all BRAF mutant lung cancers (Bracht et al. 2019). This evidence concerns the gene BRAF and lung cancer.